Moderna (NASDAQ:MRNA) Upgraded at Hsbc Global Res

Moderna (NASDAQ:MRNA) was upgraded by investment analysts at Hsbc Global Res from a “hold” rating to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.

Several other equities analysts also recently commented on the stock. Bank of America dropped their price objective on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a research note on Friday, September 13th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Leerink Partners reduced their price objective on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research report on Tuesday, September 17th. Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and dropped their target price for the company from $85.00 to $80.00 in a research report on Wednesday, August 7th. Finally, Sanford C. Bernstein began coverage on Moderna in a report on Thursday, October 17th. They set a “market perform” rating and a $55.00 price target on the stock. Three equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Moderna currently has a consensus rating of “Hold” and an average target price of $86.33.

Moderna Trading Up 7.2 %

Shares of MRNA stock opened at $39.51 on Monday. Moderna has a fifty-two week low of $35.80 and a fifty-two week high of $170.47. The stock’s fifty day moving average price is $58.56 and its two-hundred day moving average price is $96.68. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The company has a market cap of $15.20 billion, a PE ratio of -6.79 and a beta of 1.69.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. Moderna’s revenue was up 3.8% compared to the same quarter last year. During the same period last year, the firm posted ($1.39) earnings per share. Equities analysts predict that Moderna will post -9.43 EPS for the current fiscal year.

Insider Buying and Selling at Moderna

In other Moderna news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. The trade was a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 2,930 shares of company stock valued at $217,170. 15.20% of the stock is currently owned by insiders.

Institutional Trading of Moderna

Hedge funds have recently modified their holdings of the stock. State Street Corp increased its stake in Moderna by 12.1% in the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares in the last quarter. Wellington Management Group LLP increased its position in Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after buying an additional 906,114 shares in the last quarter. Two Sigma Advisers LP bought a new stake in Moderna in the 3rd quarter valued at about $23,825,000. International Assets Investment Management LLC boosted its holdings in Moderna by 10,687.1% in the third quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock worth $21,353,000 after acquiring an additional 316,552 shares in the last quarter. Finally, Matrix Capital Management Company LP grew its stake in Moderna by 60.8% in the first quarter. Matrix Capital Management Company LP now owns 730,000 shares of the company’s stock valued at $77,789,000 after acquiring an additional 276,000 shares during the period. Institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.